Mapping pneumonia research: A systematic analysis of UK investments and published outputs 1997-2013

EBioMedicine

Volumn 2, Issue 9, 2015, Pages 1193-1199

  Head, Michael G ^a   Fitchett, Joseph R ^b,c   Newell, Marie Louise ^d   Scott, J Anthony G ^b,e   Harris, Jennifer N ^f   Clarke, Stuart C ^d,g,h   Atun, Rifat ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^h UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bibliometrics; Financing; Investments; Pneumococcal; Pneumonia; Policy; Publications

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BIBLIOMETRICS; ELDERLY CARE; FUNDING; HEALTH CARE COST; HUMAN; INFLUENZA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TUBERCULOSIS; ECONOMICS; GREAT BRITAIN; INFLUENZA, HUMAN; INVESTMENT; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; PUBLICATION;

BIOMEDICAL RESEARCH; GREAT BRITAIN; HUMANS; INFLUENZA, HUMAN; INVESTMENTS; PNEUMONIA; PUBLICATIONS; TUBERCULOSIS;

EID: 84953724120     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.06.024     Document Type: Article

References (28)

1. Bill and Melinda Gates Foundation 2015 Gates Annual Letter. Our Big Bet For The Future (accessed 16 June 2015). http://www.gatesnotes.com/2015-annual-letter?page=5&lang=en.
2. Centers for Disease Control and Prevention Antibiotic resistance threats in the United States, 2013 (accessed 16 June 2015). http://www.cdc.gov/drugresistance/threat-report-2013/.
3. Enne V.I., Personne Y., Grgic L., Gant V., Zumla A. Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. Curr. Opin. Pulm. Med. 2014, 20:252-258.
4. Fonkwo P.N. Pricing infectious disease. The economic and health implications of infectious diseases. EMBO Rep. 2008, 9(Suppl. 1):S13-S17.
5. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 385:117-171. GBD 2013 Mortality and Causes of Death Collaborators.
6. Head M.G. Gross underinvestment in antibacterial research. Lancet Infect. Dis. 2014, 14:788-789.
7. Head M.G., Fitchett J.R., Cooke M.K., Wurie F.B., Hayward A.C., Atun R. UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect. Dis. 2013, 13:55-64.
8. Head M.G., Fitchett J.R., Newell M.-L., Scott J.A.G., Clarke S.C., Atun R. Investment in pneumonia and pneumococcal research. Lancet Infect. Dis. 2014, 14:1037-1038.
9. Head M.G., Fitchett J.R., Cooke M.K., et al. Investments in respiratory infectious disease research 1997-2010: a systematic analysis of UK funding. BMJ Open 2014, 4. (e004600-e004600).
10. Head M.G., Fitchett J.R., Cooke M.K., et al. Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. J. Antimicrob. Chemother. 2014, 69:548-554.
11. Howes P.D., Rana S., Stevens M.M. Plasmonic nanomaterials for biodiagnostics. Chem. Soc. Rev. 2014, 43:3835-3853.
12. Kovacs S.D., Mullholland K., Bosch J., et al. Deconstructing the differences: a comparison of GBD 2010 and CHERG's approach to estimating the mortality burden of diarrhea, pneumonia, and their etiologies. BMC Infect. Dis. 2015, 15:16.
13. Levine O.S., O'Brien K.L., Deloria-Knoll M., et al. The Pneumonia Etiology Research for Child Health Project: a 21st century childhood pneumonia etiology study. Clin. Infect. Dis. 2012, 54(Suppl. 2):S93-S101.
14. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Abraham J., Adair T., Aggarwal R., Ahn S.Y., Alvarado M., Anderson H.R., Anderson L.M., Andrews K.G., Atkinson C., Baddour L.M., Barker-Collo S., Bartels D.H., Bell M.L., Benjamin E.J., Bennett D., Bhalla K., Bikbov B. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 2095-2128.
15. Murdoch D.R., O'Brien K.L., Driscoll A.J., Karron R.A., Bhat N. Laboratory methods for determining pneumonia etiology in children. Clin. Infect. Dis. 2012, 54(Suppl. 2):S146-S152.
16. Murray C.J.L., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
17. Policy Cures Neglected disease research and development: emerging trends. Sydney (accessed 16 June 2015). http://www.policycures.org/gfinder.html.
18. Policy Cures G-finder diseases product and technologies (accessed 16 June 2014). https://g-finder.policycures.org/gfinder_report/registered/docs/G-FINDER_R&D%20Matrix_updated_2011.pdf.
19. Prendergast C., Papenburg J. Rapid antigen-based testing for respiratory syncytial virus: moving diagnostics from bench to bedside?. Future Microbiol. 2013, 8:435-444.
20. Rudan I., El Arifeen S., Bhutta Z.A., et al. Setting research priorities to reduce global mortality from childhood pneumonia by 2015. PLoS Med. 2011, 8:e1001099.
21. Sato R., Gomez Rey G., Nelson S., Pinsky B. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50years. Appl. Health Econ. Health Policy 2013, 11:251-258.
22. Scott J.A.G., Wonodi C., Moïsi J.C., et al. The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health Study. Clin. Infect. Dis. 2012, 54(Suppl. 2):S109-S116.
23. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79.
24. World Health Organization All cause mortality estimates for 2000-2012 (accessed 16 June 2015). http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html.
25. World Health Organization Priority medicines for Europe and the world - 'a public health approach to innovation' (accessed 12 June 2015). http://www.who.int/medicines/areas/priority_medicines/BP6_22Pneumo.pdf.
26. World Health Organization Antimicrobial Resistance: Global Report on Surveillance 2014 2014, World Health Organization, Geneva, (http://www.who.int/drugresistance/documents/surveillancereport/en/, accessed 16 June 2015).
27. Yao Q., Chen K., Yao L., et al. Scientometric trends and knowledge maps of global health systems research. Health Res. Policy Syst. 2014, 12:26.
28. Young A.J., Terry R.F., Røttingen J.-A., Viergever R.F. Global trends in health research and development expenditures - the challenge of making reliable estimates for international comparison. Health Res. Policy Syst. 2015, 13:7.